Inference on spatial heterogeneity in tumor microenvironment using spatial transcriptomics data.
cancer
heterogeneity
multivariate analysis
spatial transcriptomics
tissue microenvironment
Journal
Computational and systems oncology
ISSN: 2689-9655
Titre abrégé: Comput Syst Oncol
Pays: United States
ID NLM: 101775780
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
ppublish
Résumé
In the tumor microenvironment (TME), functional interactions among tumor, immune, and stromal cells and the extracellular matrix play key roles in tumor progression, invasion, immune modulation, and response to treatment. Intratumor heterogeneity is ubiquitous not only at the genetic and transcriptomic levels but also in the composition and characteristics of TME. However, quantitative inference on spatial heterogeneity in the TME is still limited. Here, we propose a framework to use network graph-based spatial statistical models on spatially annotated molecular data to gain insights into modularity and spatial heterogeneity in the TME. Applying the framework to spatial transcriptomics data from pancreatic ductal adenocarcinoma samples, we observed significant global and local spatially correlated patterns in the abundance score of tumor cells; in contrast, immune cell types showed dispersed patterns in the TME. Hypoxia, EMT, and inflammation signatures contributed to intra-tumor spatial variations. Spatial patterns in cell type abundance and pathway signatures in the TME potentially impact tumor growth dynamics and cancer hallmarks. Tumor biopsies are integral to the diagnosis and clinical management of cancer patients; our data suggest that owing to intra-tumor non-genetic spatial heterogeneity, individual biopsies may underappreciate the extent of clinically relevant, functional variations across geographic regions within tumors.
Identifiants
pubmed: 36035873
doi: 10.1002/cso2.1043
pmc: PMC9410565
mid: NIHMS1830146
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM129066
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA248122
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM149224
Pays : United States
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST The authors declare no conflict of interest.
Références
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Nat Rev Genet. 2021 Oct;22(10):627-644
pubmed: 34145435
Science. 2019 Mar 29;363(6434):1463-1467
pubmed: 30923225
Nat Biotechnol. 2020 May;38(5):629-637
pubmed: 32152598
Am J Physiol Cell Physiol. 2021 May 1;320(5):C750-C760
pubmed: 33657326
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nature. 2021 Aug;596(7871):211-220
pubmed: 34381231
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Biotechnol. 2020 Mar;38(3):333-342
pubmed: 31932730
Nucleic Acids Res. 2022 Aug 12;50(14):e82
pubmed: 35536255
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
iScience. 2022 Feb 14;25(3):103923
pubmed: 35252817
Nat Rev Cancer. 2019 Oct;19(10):553-567
pubmed: 31455893
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Nat Biotechnol. 2022 Mar;40(3):308-318
pubmed: 35132261
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Wiley Interdiscip Rev Membr Transp Signal. 2014;3(2):147-163
pubmed: 24678448
Nat Rev Clin Oncol. 2020 Nov;17(11):675-686
pubmed: 32699310
Br J Cancer. 2019 Jul;121(1):5-14
pubmed: 31110329
Nat Commun. 2018 Jun 20;9(1):2419
pubmed: 29925878
Nat Commun. 2021 May 24;12(1):3074
pubmed: 34031373
Front Genet. 2021 Oct 14;12:759832
pubmed: 34721546
Nat Methods. 2019 Oct;16(10):987-990
pubmed: 31501547